Sartorius Stedim Biotech S.A. Website

Sartorius Stedim Biotech S.A.

ENXTPA-DIM

Company Overview

Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, filtration, purification, and fluid management services; single-use and reusable hollow-fiber membrane devices, as well as presterilized assemblies for cell and gene therapy applications; and cell harvesting and various other solutions for intensified bioprocesses. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.

  • Name

    Sartorius Stedim Biotech S.A.

  • CEO

    Rene Faber

  • Website

    www.sartorius.com

  • Sector

    Life Sciences Tools and Services

  • Year Founded

    1978

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Bulls Say

  • SSB's CGT product portfolio allows the company to capitalize on long-term growth, should these therapies achieve widespread adoption.

  • Due to its market-leading position in single-use technology, SSB is well positioned to benefit from the broader adoption of this manufacturing methodology, driving revenue growth and margin expansion.

  • As a pure-play company in biopharmaceutical drug manufacturing, with a product portfolio that spans the full spectrum of biologics manufacturing, SSB differentiates itself from competitors, making it uniquely attractive to investors.

Bears Say

  • The high growth in the biopharma market increases the risk of greater competition from better-capitalized peers that have a broader product offering.

  • There is a possibility that SSB overpaid for Polyplus, potentially destroying shareholder value, if CGT adoption does not materialize.

  • Ongoing uncertainty regarding US regulators’ view on vaccines and biologics may lead to a slowdown in biotech funding, negatively affecting SSB.

Source: Morningstar Analysis - Oct 16, 2025
ENXTPA:DIM